CAPR vs VRTX

Capricor Therapeutics is undergoing a critical transition from clinical development to commercialization following the Q3/Q4 2025 FDA approval of CAP-1002 for Duchenne Muscular Dystrophy (DMD). This approval targets a multi-billion dollar market with high unmet needs, particularly for non-ambulatory patients, offering a substantial revenue pathway. The company benefits from regulatory exclusivity ...

Vertex Pharmaceuticals remains a dominant force in the Cystic Fibrosis market and is making impressive strides into high-growth therapeutic areas like gene editing (Casgevy), non-opioid pain (VX-548), and Type 1 Diabetes. Its robust pipeline, strong financials, and expanding competitive moat suggest continued growth and profitability. However, for a company with a current market capitalization of ...